Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Lyumjev ® ▼ (insulin lispro)
Lyumjev® ▼ (insulin lispro): Treprostinil Long-term Safety
In Lyumjev formulation, the microdoses of treprostinil used as an excipient induce only a local vasodilation effect.
Treprostinil was not measurable in the circulation, and no systemic effects were seen with bolus doses of Lyumjev up to 50 units in phase 1b studies.1-4
Treprostinil has been approved to treat PAH for approximately 15 years and the safety profile is established.5
In the treatment of PAH, treprostinil is used at initial doses of 1.25 ng/kg/min as a continuous infusion and achieves an average steady state concentration that is at least 200-fold higher than the levels in patients treated with Lyumjev.4,5
In the formulation of Lyumjev, microdoses of treprostinil are used as an excipient to increase blood flow at the site of injection through localized vasodilation.1-3
The commercial formulation of Lyumjev contains 10 ng of treprostinil per unit of insulin lispro in a 100-unit/mL formulation.4
1. Leohr J, Pratt E, Heilmann C, et al. Treprostinil causes local vasodilation is well tolerated, and results in faster absorption of insulin lispro [abstract]. Diabetologia. 2017;60(suppl 1):S313. http://dx.doi.org/10.1007/s00125-017-4350-z
2. Leohr J, Pratt EJ, Heilmann C, et al. A novel insulin lispro formulation containing citrate and treprostinil demonstrates faster absorption and onset of insulin action in healthy subjects [abstract]. Diabetes. 2017;66(suppl 1):A253. http://dx.doi.org/10.2337/db17-890-1488
3. Pratt E, Leohr J, Heilmann C, et al. Treprostinil causes local vasodilation, is well tolerated, and results in faster absorption of insulin lispro [abstract]. Diabetes. 2017;66(suppl 1):A253. http://dx.doi.org/10.2337/db17-890-1488
PAH = pulmonary arterial hypertension
treprostinil = Remodulin® (treprostinil) injection
URLi = ultra rapid lispro
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: July 19, 2019